Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study

This publication has 16 references indexed in Scilit:

• Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders
  JAMA Neurology, 2016
• The Immunology of Neuromyelitis Optica—Current Knowledge, Clinical Implications, Controversies and Future Perspectives
  International Journal of Molecular Sciences, 2016
• International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
  Neurology, 2015
• Demographic and clinical features of neuromyelitis optica: A review
  Multiple Sclerosis Journal, 2015
• Evaluation of aquaporin‐4 antibody assays
  Clinical and Experimental Neuroimmunology, 2014
• Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
  Journal of Neurology, 2013
• IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
  Journal of Experimental Medicine, 2005
• An open label study of the effects of rituximab in neuromyelitis optica
  Neurology, 2005
• A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
  The Lancet, 2004
• The clinical course of neuromyelitis optica (Devic’s syndrome)
  Neurology, 1999